Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest announcement is out from BeiGene Ltd ( (HK:6160) ).
BeiGene Ltd announced the grant of 42,009 Restricted Share Units (RSUs) to 192 employees under its 2016 Share Option and Incentive Plan. These RSUs, representing approximately 0.04% of the total issued shares, are part of the company’s strategy to incentivize and retain talent. The vesting of these RSUs is structured over a four-year period, reflecting BeiGene’s commitment to long-term employee engagement and alignment with company goals.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
BeiGene Ltd is a biotechnology company that focuses on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company operates in the pharmaceutical industry and is committed to improving treatment outcomes and access for patients globally.
Average Trading Volume: 6,443,610
Technical Sentiment Signal: Buy
Current Market Cap: HK$201.2B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.